Lessons learnt from broad-spectrum coronavirus antiviral drug discovery.
Expert opinion on drug discovery • Vol. 19, Issue 9 • 2024
Preclinical evaluation of the SARS-CoV-2 M inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir.
Nature microbiology • Vol. 9, Issue 4 • 2024
Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.
EClinicalMedicine • Vol. 67 • 2024
Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial.
EClinicalMedicine • Vol. 63 • 2023